ArticleCancer cell international2026
SETDB1 promotes gastric cancer progression via UPR and mTOR pathway.
Article in Cancer cell international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
SET Domain Bifurcated histone lysine methyltransferase 1 (SETDB1), a histone H3K9 methyltransferase, is frequently overexpressed in multiple malignancies, including gastric cancer (GC). However, its molecular functions and regulatory mechanisms in GC progression remain poorly defined. Here, we identified the role of SETDB1 in gastric cancer using molecular and cell biology methods, combining RNA-seq and RNC-mRNA seq. Here, we found SETDB1 was markedly upregulated in gastric cancer tissues compared with adjacent non‑tumor tissues. Functional analyses revealed that SETDB1 knockdown suppressed GC cell proliferation and migration, whereas overexpression had the opposite effect. Notably, SETDB1 promoted cell proliferation independently of its methyltransferase activity, while its enhancement of migration required enzymatic function. Mechanistically, SETDB1 activated the unfolded protein response (UPR) to stimulate c-MYC transcription and cell-cycle progression, and engaged the mTOR–4EBP1 axis to promote HIF1α translation. These findings reveal a dual regulatory role for SETDB1 in GC and identify it as a promising therapeutic target for managing gastric cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.